News | February 27, 2024
Shilpa Medicare gets Europe approval for Varenicline Tablets, 0.5mg and 1mg
Varenicline is indicated for smoking cessation in adults
Varenicline is indicated for smoking cessation in adults
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
The company intends to respond to the two minor observations within the stipulated time
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
This product has sales of about US$ 20 million in Europe
TALZENNA is the first and only PARP inhibitor approved in combination with standard of care XTANDI for mCRPC patients in the European Union
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway
Subscribe To Our Newsletter & Stay Updated
